Results 121 to 130 of about 40,111 (286)

Comparison of Time Within Therapeutic Range Using Anti-Factor Xa Versus Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin in Children. [PDF]

J Pediatr Pharmacol Ther, 2023
Haftmann RJ, Pineda EM, Hall BA, Wilson MD, Mateev SN.   +4 more
europepmc   +1 more source

Correlation between activated partial thromboplastin time and diluted Russell’s viper venom time in the presence of lupus anticoagulant [PDF]

, 2021
Luz Tarín‐Arzaga, Carlos Cruz, Martha A. Reyes-López, Omar Cantú-Martínez, Karina Vázquez-Hernández, Odra Martínez‐González, Luis Andrés González Torres, Luis Javier Marfil‐Rivera, David Gómez‐Almaguer   +8 more
openalex   +1 more source

Effectiveness and safety of antithrombin for treatment of portal vein thrombosis: Nationwide prospective surveillance of 4 years of clinical experience in Japan

Hepatology Research, EarlyView.
Abstract Aim Antithrombin (AT), a plasma protein with anticoagulant properties, has a long‐standing medical history, primarily for treatment of congenital AT deficiency. Accumulated clinical experiences suggest AT is a potential anticoagulant for thrombotic diseases. This study aimed to clarify the effectiveness, safety, and clinical significance of AT
Shoichi Matsutani, Makoto Arakawa, Susumu Nakano   +2 more
wiley   +1 more source

Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population. [PDF]

Genes (Basel), 2022
Zhang F, Mu G, Liu Z, Xie Q, Zhang H, Zhou S, Wang Z, Hu K, Wang Z, Zhao X, Cui Y, Xiang Q.   +11 more
europepmc   +1 more source

Aprotinin Prolongs Whole Blood Activated Partial Thromboplastin Time but Not Whole Blood Prothrombin Time in Patients Undergoing Cardiac Surgery

, 1995
George J. Despotis, Alexander Alsoufiev, Lawrence T. Goodnough, Demetrios G. Lappas   +3 more
openalex   +1 more source

Comparison of Russell Viper Venom–Based and Activated Partial Thromboplastin Time–Based Screening Assays for Resistance to Activated Protein C [PDF]

, 2008
A. Zara Herskovits, Susan J. Lemire, Janina A. Longtine, David M. Dorfman   +3 more
openalex   +1 more source

Activated Protein C Resistance Testing: An Update From Australasia/Asia‐Pacific

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Activated protein C resistance (APCR) represents a risk factor for thrombosis and is usually due to factor V Leiden (FVL). Clinicians may order either test (i.e., APCR or FVL) to help assess ‘thrombophilia’ in patients who present with thrombosis. APCR testing is usually achieved using clot‐based assays, whereas FVL is assessed by
Emmanuel J. Favaloro, Sandya Arunachalam, Elysse Dean, Mahzuza Salwa, Monica Ahuja, Lynne Connelly, Kent Chapman, Ronny Vong, Leonardo Pasalic   +8 more
wiley   +1 more source

Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis. [PDF]

Yonago Acta Med, 2022
Kato K, Hatayama Y, Shimohiro H, Ichikawa H, Fukuda T.   +4 more
europepmc   +1 more source

Activated Partial Thromboplastin Time as a Screening Test of Minor or Moderate Coagulation Factor Deficiencies for Canine Plasma: Sensitivity of Different Commercial Reagents

, 2000
Reinhard Mischke
openalex   +1 more source

Evaluation of Activated Partial Thromboplastin Time Mixing Studies Using Several Methods [PDF]

, 2022
Chaonan Liu, Liqin Ling, Xunbei Huang, Jian Mi, Juan Liao, Jia Jin, Xia Wang, Jing Zhou   +7 more
openalex   +1 more source